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Abstract
Background: Acylation Stimulating Protein (ASP) has been shown to influence adipose tissue
triglyceride (TG) storage. The aim was to examine ethnic differences in ASP and leptin levels in
relation to lipid profiles and postprandial changes amongst African American (AA) and Caucasian
American (CA) women matched for BMI.
Methods: 129 women were recruited in total (age 21 – 73 y): 24 non-obese (BMI < 30 kg/m2) CA,
27 obese (BMI ≥ 30 kg/m2) CA, 13 obese diabetic CA, 25 non-obese AA, 25 obese AA, and 15
obese diabetic AA. Cholesterol, HDL-C, LDL-C, apoB, glucose and insulin were measured at
baseline. TG, non-esterified fatty acids, leptin, and ASP were measured at baseline and
postprandially following a fat meal.
Results: ASP, leptin, insulin and TG were significantly increased in obese subjects within each race.
However, AA women had significantly lower ASP and TG than CA women at all BMI. Obese and
diabetic AA women had significantly lower apoB levels than CA women when compared to their
respective counterparts. For AA women, fasting ASP was positively correlated with BMI,
cholesterol, apoB, LDL-C and glucose. For CA women, fasting ASP was positively correlated with
BMI, leptin, glucose and insulin. However, for any given BMI, ASP was significantly reduced in AA
vs CA (p = 0.0004). Similarly, for any given leptin level or TG levels, ASP was significantly lower in
AA women (p = 0.041 and p = 0.003, respectively).
Conclusion:  CA women have higher baseline TG levels and an earlier TG peak that is
accompanied with higher ASP levels suggesting increased ASP resistance, while AA women have
lower baseline TG levels and a later TG peak at lower ASP levels suggesting increased ASP
sensitivity. This may explain why AA women may have fewer metabolic complications, such as
diabetes and CVD, when compared to their Caucasian counterparts at the same level of obesity.
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Background
There has been an increase in the general prevalence of
obesity from 15% during NHANES II (1976–1980) to
more recent estimates of nearly 31% during NHANES
(1999–2000)[1]. There are several risk factors that have
been associated with obesity, including hyperinsuline-
mia, diabetes, hyperlipidemia, hypertension, and cardio-
vascular disease. In addition to the increased morbidity,
approximately 325 000 deaths in the United States each
year among nonsmokers are attributed to obesity [2,3].
Approximately 49% of African American women in the
US are obese [4]. However, not all overweight women,
either African American or Caucasian American, develop
the metabolic abnormalities associated with their excess
weight. Specifically, while the prevalence of obesity is
much higher in African American women than Caucasian
American women by approximately 15% [5], and insulin
resistance/hyperinsulinemia is also higher [6,7]; the inci-
dence of diabetes is only 5% higher [5]. In addition, prev-
alence of cardiovascular disease appears to be lower in
African American women [8,9]. While it has been sug-
gested that type 2 diabetes is associated with an acceler-
ated rate of development of cardiovascular disease,
particularly in African American women [10], nonetheless
it is important to note that the mortality rate associated
with obesity is actually higher in Caucasian American
than in African American women [11]. Therefore,
although there is an increased prevalence of risk factors
for CVD (obesity and diabetes), this does not result in an
equivalent increase in prevalence of CVD in African Amer-
ican women compared to Caucasian women.
Interestingly, when matched for BMI, percent fat, and
waist-to-hip ratio or waist circumference, the frequency of
cardiovascular disease risk factors associated with abdom-
inal obesity (impaired glucose tolerance and dyslipi-
demia) is still lower in abdominally obese African
American women vs. Caucasian American women [8,9].
Studies suggest that differences in central fat distribution,
in particular visceral obesity, may play a role [9]. None-
theless there still remains a controversy with respect to the
differences in the levels and metabolic activity of visceral
vs. subcutaneous fat having some, if any, responsibility
for the ethnic differences seen between African and Cau-
casian women [12,13].
In recent years, adipokines have increasingly attracted
attention for their potential roles in obesity and related
metabolic diseases. Decreased adiponectin is associated
with obesity, diabetes, cardiovascular disease and breast
cancer [4]. Further, racial differences have been reported
in a number of studies, which indicate that AA have lower
adiponectin levels that CA [14-16] although not all stud-
ies agree [17]. Leptin, the product of the ob gene, is pro-
duced by adipose tissue and secreted into the circulation
[18]. Leptin functions as a part of a lipostatic signaling
pathway that regulates energy homeostasis both centrally
and in the periphery (review[19]). Both leptin mRNA and
plasma leptin correlate positively with BMI and adiposity
in humans [20]. Weight loss in obese subjects results in a
decrease in serum leptin concentrations [20]. Circulating
leptin concentrations decrease independently of modest
changes of body fat content during short-term periods of
fasting and are rapidly normalized when the fasting
period is terminated [21,22]. To date, comparison of lep-
tin in AA vs CA has produced mixed data, with increased
[23,24], decreased [25], or no change in leptin [26-28]
between the groups. We have previously demonstrated
ethnic differences in both adiponectin and leptin in Asian
Indians compared to Caucasians [29]. Differences in
inflammatory factors, several of which are also produced
by adipose tissue, have also been evaluated. Several recent
studies provide varied data with respect to inflammatory
factors, one demonstrating that African American women
presented with increased C-reactive protein, IL-6 and
fibrinogen relative to Caucasian counterparts [30], while
another presented data that African American women had
lower visceral adipose tissue, insulin sensitivity, TNFalpha
and soluble TNFR-1 [31]. Further, studies in adipose tis-
sue have demonstrated that there was no difference in
mRNA expression or in adipose tissue explant secretion of
IL-8, PGE2 and IL-6 in African American women vs Cau-
casian women [23].
Acylation stimulating protein (ASP), also an adipokine, is
produced within the micro-environment of adipocytes
and increases within this environment postprandially as
demonstrated using in vivo arterial-venous gradients
across a subcutaneous adipose tissue bed in humans
[32,33]. Furthermore, ASP production and the respon-
siveness of the adipocyte increased as a result of adipocyte
differentiation [34]. ASP acts in an autocrine manner on
adipocytes to increase triglyceride synthesis, via stimula-
tion of fatty acid esterification and glucose transport [35].
ASP also inhibits hormone sensitive lipase independently
and additively to insulin in adipocytes. These ASP effects
are mediated through a G-protein coupled receptor
(C5L2) [36,37]. There are several studies that demonstrate
a strong correlation between plasma ASP and BMI in a
general population [35] although racial differences are
unknown.
In the present study we examined ASP and leptin levels in
relation to fasting and postprandial lipid profiles amongst
non-obese, obese, and obese diabetic African American
and Caucasian American women matched for BMI.
Methods
Subjects
Six groups of women participated in this study: non-obese
(body mass index, BMI < 30) African Americans, non-
obese Caucasian Americans, obese (BMI >= 30) AfricanNutrition & Metabolism 2009, 6:18 http://www.nutritionandmetabolism.com/content/6/1/18
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Americans, obese Caucasian Americans, obese diabetic
African Americans, and obese diabetic Caucasian Ameri-
cans. Classification of type 2 diabetes was done with the
criteria of the National Diabetes Data Group [38]. Dura-
tion of diabetes was greater than three years. Over 40% of
those with type 2 diabetes were receiving some form of
pharmaceutical therapy in addition to diet and physical
activity recommendations, all of which was suspended
two weeks prior to sample collection. Data from some of
these subjects was used in a previous study that reported
only on postprandial TG [39]. The participants were free
of vascular disease, cancer or emotional distress, and were
not taking any medication that may affect carbohydrate or
lipid metabolism. The subjects were not taking hormone
replacement therapy or birth control pills. The African
Americans group was matched on age and stratified to
subjects in the corresponding Caucasian group according
to BMI. The women who participated in this study were
recruited consecutively over a period of 18 months from
the Department of Surgery at East Carolina School of
Medicine. African American women were included in this
study only if their parents and grandparents were African
American descent. Body mass and height were recorded to
the nearest 0.1 kg and 0.1 cm, respectively, and BMI calcu-
lated. One hundred and twenty-nine women were
recruited in total: 24 non-obese Caucasian, 27 obese Cau-
casian, 13 obese diabetic Caucasian, 25 non-obese Afri-
can, 25 obese African, and 15 obese diabetic African
Americans. Written consent was obtained from all the
subjects after they were informed of the nature of the
study. The Institutional Review Board for human subject
research approved the protocols used in this study.
Fasting blood samples were collected from all the women
in the six groups after a 12-hour fast. The plasma was ana-
lyzed for triglyceride (TG), total cholesterol (TC), HDL-C,
LDL-C, apolipoprotein B (apoB), non-esterified fatty acids
(NEFA), glucose, insulin, ASP, and leptin concentrations
as described below.
Postprandial State
In the second part, we evaluated the postprandial
response to a fat-load challenge in 10 non-obese Cauca-
sian, 8 obese Caucasian, 10 non-obese African, and 7
obese African Americans. A blood sample was taken from
each volunteer after an overnight fast (basal state). All
basal plasma was analyzed for TG, TC, HDL-C, LDL-C,
apoB, NEFA, glucose, insulin, ASP, and leptin concentra-
tions. Each volunteer then ingested a fatty meal, as previ-
ously described (16). In brief, each subject was given a
liquid fatty meal (85.5% of calories from fat), which was
prepared from 350 mL heavy whipping cream (39.5% wt/
vol fat), 2 tablespoonfuls of chocolate-flavored syrup, 1
tablespoonful of sugar, and 1 tablespoonful of instant
nonfat dry milk. Subjects consumed 175 mL of this fatty
meal calculated in 1 m2 of body surface area to provide 65
g fat/m2 body surface. The mean dose of the fat meal
administered was 197 mL.
Postprandial blood samples were drawn via an indwelling
intravenous catheter at 2, 4, 6 and 8 hours after ingestion
of the fatty meal. Blood was collected from each subject
and a preservative solution containing sodium azide (50
mg/mL) and aprotinin (1 TIU/mL) was added. Plasma
was prepared by centrifugation, aliquoted and stored at -
80°C until analyzed for TG, NEFA, ASP, and leptin.
Plasma Analyses
Plasma TG were measured enzymatically on an IL Mon-
arch centrifugal analyzer (Instrumental Laboratory, War-
rington, Chesire, UK) with correction for free glycerol
[40]. Plasma TC was measured with a commercial enzy-
matic colorimetric method (cholesterol 50 kit; Sigma,
Poole, UK). Plasma NEFA was measured by an enzymatic
method (Wako NEFA kit; Alpha Laboratories, Eastleigh,
UK). HDL-C concentrations were measured by a commer-
cial enzymatic colorimetric kit (Roche Diagnostics, Laval,
Quebec, Canada). Plasma HDL-C was separated accord-
ing to Gidez et al [41] by heparin/manganese chloride
precipitation. Total apoB was measured by a competitive
enzyme-linked immunosorbent assay (ELISA), using rab-
bit anti-human apoB antibody (in house), a commercial
standard (837237; Boehringer Mannheim, Laval, Quebec,
Canada), and controls (Precipath 1285874 and Preci-
norm 781827: Boehringer Mannheim). Plasma insulin
was measured by microparticle enzyme immunoassay
(IMX; Abbott Labs, Abbott Park, IL). Samples were ana-
lyzed spectrophotometrically for glucose (16-UV; Sigma
Chemical Co., St. Louis, MO). Glucose was assayed in
serum samples by a commercial enzymatic colorimetric
kit (Sigma, St. Louis, MO). Plasma ASP was assayed by an
in-house ELISA assay, using a monoclonal antibody as
capture antibody and a polyclonal antibody as detecting
antibody as previously described [42,43]. Leptin was
measured by radioimmunoassay (Linco, St. Charles,
MO).
Calculations and Statistics
Body mass and height were recorded to the nearest 0.1 kg
and 0.1 cm, respectively, and BMI calculated as weight
(kg)/height (m)2. Plasma LDL cholesterol was calculated
according to the Friedewald equation as evaluated by
Schectman, Patsches, and Sasse [44]. To examine the main
effects of race and group, a two-way repeated measure
analysis of variance was performed (two-way ANOVA,
with all pairwise multiple comparisons using Bonferoni t-
tests). For the 8 hour fat-load, when the equal variance test
failed, data was transformed to the trapezoid area under
the curve (AUC), and the means compared by one-way
ANOVA. Pearson correlation was performed to examineNutrition & Metabolism 2009, 6:18 http://www.nutritionandmetabolism.com/content/6/1/18
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correlations amongst plasma components. One-way
ANOVA was then performed when there was a significant
effect of race or group. Statistical analysis was performed
with SigmaStat (Jandel, San Rafael, CA). Significance was
set at P < 0.05.
Results
As seen in Table 1, non-obese, obese and obese diabetic
AA subjects were matched to CA based on age and body
mass index (BMI). BMI for the non-obese subjects was sig-
nificantly less than the obese and obese diabetic subjects
in each race. Fasting plasma hormones and lipid profiles
of the subjects are also shown. No significant difference
was found for glucose, NEFA, total cholesterol, apoB,
LDL-C, or LDL-C/apoB compared within each race
between obese and non-obese. TG (p < 0.02), and HDL (p
< 0.02) in non-obese subjects were significantly different
than their obese and diabetic obese counterparts within
each race. Furthermore, glucose, NEFA, total cholesterol,
apo B and LDL-C in obese diabetic subjects was signifi-
cantly different from both their non-obese (p < 0.02) and
obese (p < 0.05) counterparts in each race. Interestingly,
with CA women, the insulin levels in obese diabetic sub-
jects were significantly different from both their non-
obese (p < 0.02) and obese (p < 0.05) counterparts. In AA
women, insulin in non-obese subjects was significantly
lower than their obese and diabetic obese counterparts. In
the diabetic subjects within each race, HDL (p < 0.02)
demonstrated a difference only with respect to the non-
obese counterparts and not the obese. Further, in AA
women, the average TG in the obese diabetic group was
significantly different from both the non-obese (p < 0.02)
and obese (p < 0.02) matched groups. In the CA women,
TG in the obese diabetic group was significantly different
only from the non-obese (p < 0.02) group. There was a
race effect demonstrated for non-obese and obese groups
between AA women and CA women in that AA women
had lower TG than CA women. Obese AA women had sig-
nificantly lower apo B levels than obese CA women. Con-
sequently, AA women had a higher LDL-C/apoB ratio (p <
Table 1: Age, BMI, Plasma Hormones and Lipid Profile of Subjects
AA women CA women
Non-obese Obese Obese Diabetic Non-obese Obese Obese Diabetic
n 25 25 15 24 27 13
Age (yr) 40.4 ± 2.2 37.0 ± 1.4 45.3 ± 2.0 37.0 ± 2.5 35.2 ± 1.5 39.9 ± 3.1
BMI (kg/m2) 24.2 ± 0.6 38.6 ± 2.0** 45.9 ± 3.0** 22.5 ± 0.4 46.5 ± 3.1** 47.0 ± 3.3**
Glucose (mg/dL) 84.2 ± 2.3 91.2 ± 2.6 209.8 ± 15.5*a 85.1 ± 3.3 96.2 ± 5.1 168.5 ± 19.1*a
TG (mg/dL) 51.7 ± 4.8†† 78.3 ± .6*†† 120.0 ± 12.4*a 85.5 ± 7.0 123.4 ± 14.1* 131.9 ± 17.1*
NEFA(mM) 0.503 ± 0.06 0.643 ± 0.08 1.059 ± 0.162*a 0.552 ± 0.05 0.620 ± 0.05 0.799 ± 0.093*a
TC (mg/dL) 173.7 ± 9.1 158.4 ± 8.3 205.4 ± 9.5*a 156.0 ± 5.8 169.5 ± 8.2 193.5 ± 11.7*a
Apo B (mg/dL) 79.7 ± 8.6 64.7 ± 3.8† 97.4 ± 5.6*a 75.0 ± 7.2 88.9 ± 9.0 105.0 ± 5.2*a
HDL-C (mg/dL) 59.6 ± 4.3 40.3 ± 4.1* 37.6 ± 2.8* 50.8 ± 3.6 38.8 ± 3.7* 33.5 ± 2.9*
LDL-C (mg/dL) 103.7 ± 8.6† 102.5 ± 7.0 143.8 ± 8.2*a 88.1 ± 4.1 105.9 ± 7.5 133.6 ± 12.1*a
LDL-C/ApoB 1.44 ± 0.14† 1.63 ± 0.07† 1.53 ± 0.05† 1.33 ± 0.12 1.31 ± 0.07 1.34 ± 0.08
Insulin (pM) 7.8 ± 1.3 17.8 ± 2.4* 19.7 ± 4.6* 6.8 ± 0.8 16.5 ± 1.9* 26.9 ± 4.6*a
Leptin (ng/mL) 16.4 ± 1.6 54.0 ± 6.9* 45.8 ± 6.7* 20.7 ± 4.8 58.4 ± 5.1* 43.0 ± 4.8*
ASP(nM) †  18.6 ± 1.1†† 26.3 ± 2.4*†† 27.5 ± 3.1*†† 26.9 ± 2.5 34.9 ± 2.9* 40.1 ± 4.8*
Values were measured from fasted plasma and are shown as averages ± SEM for each group for CA (Caucasian American) and AA (African 
American), where * p < 0.05 and ** p < 0.01 for comparison with respect to non-obese subjects or a p < 0.05 with respect to obese non diabetic 
subjects within each race. An effect of race was demonstrated where † p < 0.05 or †† p < 0.01.Nutrition & Metabolism 2009, 6:18 http://www.nutritionandmetabolism.com/content/6/1/18
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0.05) than CA women in every group (Table 2), thus
showing a race effect.
With respect to hormones, the average levels of insulin (p
< 0.02) and leptin in non-obese subjects were significantly
lower than their obese counterparts within each race.
Obese and obese diabetic individuals had significantly
higher levels of ASP (p < 0.02) than their non-obese coun-
terparts for each race (Figure 1A). In all groups (non-
obese, obese and obese diabetic) AA women had signifi-
cantly lower ASP levels (p < 0.006) than CA women. A
race effect was not apparent for the other parameters
measured, including leptin. ASP was the only hormone-
like parameter that consistently demonstrated a race
effect.
Table 2 presents Pearson correlation analysis between ASP
and various plasma parameters. In AA women, ASP
strongly correlated with lipid parameters (TG, cholesterol,
apoB and LDL-C), while in CA women there were only
correlations between ASP and leptin or insulin. A signifi-
cant positive correlation between ASP and BMI was
present in both races (CA p = 0.02, AA p = 0.036, Figure
1B and 1C). Interestingly, for any given BMI (ranging
from non-obese to obese), ASP is always less in AA vs. CA
women (Figure 1D, p < 0.0004). Similarly, for any given
plasma TG level, ASP is always lower in AA (p < 0.003),
and for any given leptin level, ASP is always lower in AA
(p = 0.041).
Pearson correlation analysis between leptin and plasma
parameters was also performed (Table 2). Leptin posi-
tively correlated with BMI in both races (AA p < 0.0001,
CA p < 0.0001). Interestingly, there was a difference
between AA and CA women in that leptin was signifi-
cantly correlated with HDL-C (r = -0.301, p = 0.015) and
insulin (r = 0.219, p = 0.04) only in AA women. In CA
women, leptin was marginally correlated to TG.
A fat load was given to four groups of subjects (non-obese
AA: n = 7, obese AA: n = 10, non-obese CA: n = 8, obese
CA: n = 10). The AA and CA groups were matched for BMI.
TG, NEFA, leptin and ASP were measured at fasting and
up to eight hours after the meal. As shown in Figure 2A,
Table 2: Pearson Correlations with Respect to ASP and Leptin within CA and AA women
AA women CA women AA women CA women
R/P ASP ASP Leptin Leptin
n 65 64 65 64
BMI r = 0.260
p = 0.036
r = 0.357
p = 0.015
r = 0.693
p < 0.0001
r = 0.737
p < 0.0001
Leptin ns r = 0.362
p = 0.014
--
TG r = 0.305
p = 0.014
ns ns r = 0.120 
p = 0.05
TC r = 0.388
p = 0.002
ns ns ns
Apo B r = 0.481
p = 0.001
ns ns ns
HDL-C ns ns r = -0.301
p = 0.015
ns
LDL-C r = 0.340
p = 0.006
ns ns ns
Glucose r = 0.256
p = 0.041
r = 0.248
p = 0.047
ns ns
Insulin ns r = 0.358
p = 0.004
r = 0.219
p = 0.04
ns
Values of correlation coefficient (R) and p values (P) are shown for significant correlations only, where ns indicates non-significant.Nutrition & Metabolism 2009, 6:18 http://www.nutritionandmetabolism.com/content/6/1/18
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all groups demonstrated a similar pattern of NEFA. The
levels of NEFA peaked at six hours (p < 0.01 compared to
zero, 2 hours and 4 hours).
By contrast, there were significant differences in the TG
curves, as seen in Figure 2B. In general, non-obese AA
women had lower plasma TG levels than non-obese CA
women at basal and 2, 4, 6, and 8 hours postprandially.
Obese subjects had a higher area-under-the-curve for their
TG levels after the fatload curve when compared to their
respective non-obese counterparts (p = 0.0008) for both
AA and CA women (AA non-obese vs AA obese p < 0.01
and CA non-obese vs. CA obese p < 0.01 by RM-ANOVA).
Plasma TG in AA women (non-obese and obese) peaked
at six hours (AA: p < 0.05 for 6 hours vs. 8 hours), while
in CA women it peaked at four hours (p < 0.01 for 4 hours
vs. 8 hours). There was a significant difference observed
between races (AA vs CA: p = 0.006) and body size (obese
vs non-obese: p < 0.0001) related to the total area-under-
the-curve for postprandial TG over time. Baseline levels of
TG were correlated with the total area under the TG time
curve for all women (r2 = 0.531, p = 0.001).
ASP and leptin were followed during the course of the fat
load. The levels of leptin (Figure 2D) did not change sig-
nificantly over time. Not surprisingly, there were differ-
ences between non-obese and obese subjects within each
race (AA: p < 0.001, CA: p < 0.001). Although there was
no difference in the leptin time curves between non-obese
AA women and non-obese CA women, obese AA women
had significantly lower levels of leptin at all time points
when compared to obese CA women (p < 0.001).
AA women and CA women demonstrated different pat-
terns for ASP time curves (Figure 2C). Both non-obese and
obese AA women tended to have lower basal ASP levels
and a more rapid decline in ASP from basal to four hours
as well as from basal to eight hours when compared to the
CA women (p = 0.047). Fasting levels of ASP positively
correlated with the decrease in ASP levels over 8 hours for
both AA and CA women (r = 0.898, p < 0.001 for AA and
r = 0.969, p < 0.001 for CA), with the higher the fasting
ASP, the greater the decrease at 8 hours. The drop in ASP
from baseline to 8 hours correlated with basal TG (r =
0.620, p = 0.006) in CA women only. In addition, the area
under the ASP time curve was significantly greater in
obese women when compared to their non-obese coun-
terparts within race (AA non-obese vs. AA obese, p < 0.05,
CA non-obese vs. CA obese p < 0.05). Furthermore, AA
women demonstrated lower postprandial ASP AUC than
CA women regardless of their BMI (Figure 2C inset, non-
obese AA vs. non-obese CA, p < 0.01 and obese AA vs.
obese CA, p < 0.001 by ANOVA).
Discussion
Although the prevalence of obesity is greater in African
American women than in Caucasian American women,
AA women do not necessarily have a corresponding pro-
portional increase in the risk of metabolic complications
associated with obesity when both groups are matched for
BMI, body fat, waist circumference or waist-to-hip circum-
ference ratio [9]. In the present study, within each race, the
average levels of insulin, leptin, ASP, TG, and HDL-C in
non-obese subjects were significantly different from their
obese counterparts. Notably, a race difference was evident
whereby the AA women had significantly lower ASP, fast-
ing TG, and apoB levels than CA women at all BMI. Fur-
thermore, TG time curve profiles showed similar trends
within race but differed between races. The area-under-
the-curve for TG was lower in non-obese AA women indi-
cating faster TG clearance. In addition, ASP AUC was pos-
itively correlated with baseline ASP levels, with lower ASP
AUC in AA women. Moreover, in AA women, ASP posi-
tively correlated with BMI, TG, TC, apoB, LDL-C and glu-
cose, whereas for CA women, ASP positively correlated
with BMI, leptin, glucose and insulin. Taken together, this
study suggests that AA women have more efficient TG
clearance with lower ASP levels, suggesting increased ASP
sensitivity.
Fasting ASP values in non-obese, obese and obese diabetic  Caucasian American (CA) and African American (AA)  women relative to BMI Figure 1
Fasting ASP values in non-obese, obese and obese 
diabetic Caucasian American (CA) and African 
American (AA) women relative to BMI. Fasting blood 
samples were collected and ASP measured in CA (n = 64) 
and AA (n = 65) women. Panel A: Average ± SEM is given for 
each group where * p < 0.05 vs. respective lean control 
group, and †† p < 0.01 for AA vs. CA. Panels B and C: Corre-
lation between plasma ASP and BMI is given for CA (Panel B, 
p = 0.015), AA (panel C, p = 0.036). Panel D: Correlation 
between ASP and BMI was significantly different between AA 
and CA (p = 0.0004).
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The question remains as to what biochemical factors may
explain the difference between AA women and CA women
noted above. Adipose tissue stores are determined by the
balance between fat utilization and fat storage. AA women
have been reported to show decreased in vivo fatty acid
oxidation [45], a state that was shown in vitro to be asso-
ciated with lower skeletal muscle FA oxidation [46]. Non-
obese AA have decreased levels of circulating adiponectin
as well, an adipokine associated with increased fatty acid
oxidation [16]. These factors may enhance shunting of
fuel from muscle to adipose tissue for storage, and con-
tribute to the development and maintenance of obesity in
AA women.
In adipose tissue, the balance of TG stores is determined
by the opposing reactions of TG synthesis and lipolysis.
While a lower basal lipolytic rate in adipose tissue from
AA women vs CA women has been demonstrated [47,48]
stimulation of hormone-stimulated lipase resulted in
equal lipolytic activity between races [39]. Neither differ-
ences in beta-adrenergic receptors nor eNOS (both of
which can influence lipolysis) could explain the AA vs CA
difference [49,50], although the potential exists for a
greater inhibition of lipolysis by alpha-adrenerigc recep-
tors in obese AA women[51]. Overall, this suggests that
changes in lipolysis may not explain the racial differences
in adipose tissue maintenance.
The differences in the metabolic abnormalities between
AA women and CA women may be related to racial differ-
ences in the rate of triglyceride clearance and adipose tis-
sue storage. Both non-obese and obese AA women have
an increased capacity to synthesize TG in omental adipose
tissue compared to Caucasian American women [13]. In a
previous study by Barakat and colleagues, in a separate
group of women, lipoprotein lipase mass was shown to be
increased in subcutaneous adipose tissue from obese AA
women, and postheparin plasma LPL activity was higher
in non-obese AA than in non-obese CA, and was associ-
ated with a more rapid clearance of postprandial triglycer-
ides [39]. Further, increased mRNA and protein of CD36
(a fatty acid transporter), FATP4 (fatty acid binding pro-
tein) and PPARγ in AA vs CA women in visceral fat may
also contribute to increase capacity for fatty acid uptake
and increased TG storage [52].
ASP has previously been shown to be positively correlated
to BMI, with obese individuals having higher ASP levels
[35]. This was also true in both AA and CA women. ASP
directly stimulates TG synthesis through enhanced fatty
acid esterification and glucose transport in human adi-
pocytes and preadipocytes [35]. ASP also increases the
efficiency of LPL action by enhancing uptake of fatty acids
and protecting LPL from product inhibition [53]. ASP has
been shown to increase postprandially within the micro-
environment of the adipose tissue, correlating with
increased TG uptake into adipose tissue [32,43]. In a
recent study, fasting ASP was shown to be directly corre-
lated with postprandial TG clearance in both men and
women [54,55] with a lower fasting ASP associated with a
more efficient TG clearance. Further, changes in metabolic
function, such as thyroid status where hypothyroidism is
associated with increased BMI and ASP [56], or in rosigli-
tazone treatment, which improves metabolic function in
type 2 diabetic subjects [57], also resulted in a decreased
fasting and postprandial adipose tissue production of
ASP. As the function of ASP is to increase adipose tissue
TG esterification, and as AA circulating ASP levels remain
Postprandial changes in plasma triglycerides, non-esterified  fatty acids, ASP and leptin Figure 2
Postprandial changes in plasma triglycerides, non-
esterified fatty acids, ASP and leptin. Blood samples 
were collected after a 12 hour fast and then subsequently at 
2, 4, 6, and 8 hours after ingestion of a fatty meal in 4 groups: 
African American non-obese women (AA-L, filled squares, 
solid line, n = 10). African American obese women (AA-O, 
filled circles, solid line, n = 7), Caucasian American non-
obese women (CA-L, open squares, dotted line, n = 10), and 
Caucasian American obese women (CA-O, open circles, dot-
ted line, n = 8) for triglyceride (A), non-esterified fatty acids 
(B), ASP (C) and leptin (D) expressed as averages ± SEM. 
Non-obese and obese groups were matched for BMI 
between races. Significant differences were as follows: panel 
A: TG time course p < 0.01 for AAL vs AAO and CAO, and 
TG area-under-the curve (AUC)(insert) ** P < 0.01 *** p < 
0.001; Panel B: NEFA time course: * p < 0.01 for 6 hours vs. 
zero, 2 hours and four hours; Panel C: ASP time course and 
ASP AUC (insert). There was a significant race affect with 
CA-L and CA-O women having significantly greater ASP 
AUC than the AA counterparts, * p < 0.05, ** p < 0.01 and 
*** 0.001 vs AA-L and # p < 0.05 vs. CA-O; Panel D: Leptin 
time course was significantly differences between non-obese 
and obese subjects within each race (AA: p < 0.001, CA: p < 
0.001), further, AA-O were significantly lower than CA-O at 
all time points, p < 0.001.
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lower, this could suggest that AA also have increased ASP
sensitivity.
Conclusion
In conclusion, the differences in ASP and TG profiles
between races supports that there are race differences in
lipid metabolism. The results suggest that AA women have
a more efficient synthetic capacity as documented previ-
ously by increased triglyceride synthesis, LPL, CD36,
FATP4, and PPARγ and, in the present stufy, lower circu-
lating ASP, suggesting increased ASP sensitivity. Overall,
AA women may have a more efficient fatty acid trapping
than CA women and this may contribute both to develop-
ment and maintenance of obesity, and to the lower pro-
portional increase in metabolic complications such as
diabetes and CVD in African American women compared
to their Caucasian counterparts at the same level of obes-
ity.
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